• Enzymatica’s Q3 2026 operating loss narrowed 53% year over year to SEK 3.9 million.
• Net sales fell year over year to SEK 14.57 million, while UK net sales climbed 51% to SEK 1.7 million.
• Operating expenses dropped 24% year over year to SEK 13.33 million, mainly due to lower selling and administrative expenses.
• Following the quarter, first deliveries reached STADA for Germany, while a MedonyX partnership expanded ColdZyme’s reach to Jordan and Iraq.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Enzymatica AB published the original content used to generate this news brief on October 29, 2026, and is solely responsible for the information contained therein.